News

December 19, 2017

Consolidation of Group Production Functions (Absorption-type Demerger and Absorption-type Merger among the Wholly Owned Subsidiaries of the Company)

November 22, 2017

Notice on Production and Marketing License Agreement with Vietnamese Pharmaceutical Company

November 6, 2017

Supplementary information (Nov 6, 2017)

November 6, 2017

Summary of Consolidated Financial Results(For the Second Quarter Ended September 30, 2017)　[Japanese Standard]

September 28, 2017

Establishment of a Subsidiary

July 31, 2017

Summary of Consolidated Financial Results (For the first Quarter Ended Jun 30,2017)［Japanese Standard］

July 31, 2017

Consolidated Financial Results (For the first Quarter Ended Jun 30,2017)- Supplementary Information

May 11, 2017

Summary of Consolidated Financial Results

May 11, 2017

Consolidation of Group Production Functions

April 11, 2017

Kyorin acquired licenses from Merck & Co., Inc., Kenilworth, N.J., U.S.A. for Investigational Therapy for Overactive Bladder (Code:KRP-114V) in Asia

February 22, 2017

Change of Representative Director and President at ActivX Biosciences, Inc.

February 22, 2017

Establishment of a Representative Office in the Republic of Indonesia

February 3, 2017

Summary of Consolidated Financial Results (For the third Quarter Ended Dec 31,2016)［Japanese Standard］

February 3, 2017

Revision of Consolidated Financial Forecasts

February 3, 2017

Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2017

January 11, 2017

Conclusion of Agreement on Business Alliance for Sale of Hand-Sanitizers